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INTRODUCTION
One-third of patients with bladder cancer (BCa) exhibit mus-
cle invasion at diagnosis, and half of them develop distant me-
tastasis to the lungs, liver, and bone within 2 years.1 Cisplatin-
based systemic chemotherapy is the first-line treatment option 
for metastatic BCa. Although the initial response rate for cispl-
atin chemotherapy is up to 50–70%, most BCa patients experi-
ence recurrence, with a 5-year survival rate for metastatic BCa 
of only 6%.2-4 In the last two decades, treatment options for 
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strong synergy between the two drugs with a synergy volume of 201.84 μM/mL2%. The combination therapy resulted in G1-phase 
cell cycle arrest and caspase-dependent apoptosis confirmed by the Western blot.
Conclusion: HSP90 inhibitor monotherapy and in combination with the PI3K/mTOR survival pathway inhibitor NVP-BEZ235 
shows a synergistic antitumor effect in cisplatin-resistant bladder cancers, eliciting cell cycle arrest at the G1 phase and induction 
of caspase-dependent apoptotic pathway. 
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these patients have not improved drastically. This may be due 
to drug resistance that often reduces the efficacy of cisplatin 
to cancer cells. At the same time, up to 50% of patients with 
BCa are ineligible for cisplatin, mostly because of decreased 
renal function. Over the past few decades, numerous trials 
have been conducted to overcome cisplatin resistance and to 
reduce the effective dose for preserving renal function. 
Heat shock protein 90 (HSP90) is an intracellular protein 
that plays a crucial role as a chaperone. It acts in post-transla-
tional maturation and activation of many oncogenic client 
proteins. In healthy cells, the HSP90 chaperone complex is 
thought to work as a facilitator of cellular responses to extra-
cellular signals. In cancer cells, HSP90 activates many onco-
genic client proteins, stimulating cell survival, growth, and in-
vasiveness. Therefore, HSP90 inhibitors are considered 
promising therapeutic options and are being investigated for 
use in several cancers preclinically.5-8 However, HSP90 inhibi-
tor monotherapy has been found to show suboptimal inhibi-
tion of target proteins,9 and thus, combined approaches may 
be required.10 Since some HSP90 targets have chemoprotec-
tive activity, the combination of an HSP90 inhibitor with a 
standard chemotherapeutic agent could markedly increase 
the in vivo efficacy of the therapeutic agent.11 As HSP90 acts on 
ERBB2 and its downstream signals (RAS-MEK-MAPK, PI3K-
Akt-mTOR), targeting both HSP90 and its downstream path-
way could be potential strategy with which to overcome cispl-
atin resistance in human BCa.12,13 
The PI3-Akt-mTOR signaling axis is known as a significant 
survival pathway. It is considered an essential target in cancer 
therapy since it plays a critical role in development, progres-
sion, metastasis, and chemoresistance. Several studies have 
shown a synergistic antitumor effect between PI3K or mam-
malian target of rapamycin (mTOR) inhibitors and conven-
tional chemotherapies in chemo-naïve or resistant cancers, like 
melanoma, nasopharyngeal, and ovarian cancers. Unfortunate-
ly, PI3K or mTOR inhibitor monotherapy has not shown sig-
nificant clinical outcomes as in HSP90 inhibitor monotherapy. 
In BCa, however, simultaneous dual inhibition of PI3K/mTOR 
using NVP-BEZ235 has been found to exert a synergistic antitu-
mor effect.3 Based on these results, we suspect to observe some 
synergism when both PI3K/mTOR dual inhibitor and HSP90 
inhibitor are coupled in the treatment of cisplatin-resistant 
bladder cancer cells.
In the present study, we investigated the synergistic effects of 
combining the PI3K/mTOR pathway inhibitor NVP-BEZ235 and 
the HSP90 inhibitor 17-DMAG in cisplatin-based chemotherapy.
MATERIALS AND METHODS
Cell lines and reagents 
Human bladder cancer cells (HTB9, J82, SW1710, T24, HTB5, 
UMUC14, and 253J) were maintained in MEM, DMEM, or 
RPMI-1640, containing 10% fetal bovine serum (GE Healthcare 
Hyclone, UT, USA), 100 U/mL penicillin, and 100 mg/L strepto-
mycin (Gibco BRL, Grand Island, NY, USA). Cells were incubat-
ed at 37°C in a humidified 5% CO2 atmosphere. UMUC14 cells 
were donated by Professor E.S. Lee (Seoul National University, 
Seoul, Korea), and all other cell lines were obtained from Ko-
rean Cell Line Bank (Seoul, Korea) or American Type Culture 
Collection (Manassas, VA, USA). The cisplatin-resistant T24R2 
cell line was achieved by desensitizing T24 cells to cisplatin 
up to a concentration of 2 µg/mL (Fig. 1). 
NVP-BEZ235 was provided by Novartis Pharmaceuticals 
Inc. (Basel, Switzerland), and 17-DMAG was purchased from 
Selleckchem (Selleckchem, Boston, MA, USA). NVP-BEZ235 
compound was dissolved in 100% DMSO at 85°C to prepare a 
10 mM stock solution and stored at 4°C until ready for use. An-
tibodies for p-AKT (ser473), AKT, p-mTOR (Ser2448), mTOR, 
p-GSK-3β (Ser9), GSK-3β, p-4E-BP1 (Thr37/46), 4E-BP1, p-
MEK1/2 (Ser217/221), MEK1/2, p-ERK1/2 (Thr202/Tyr204), 
ERK1/2, cleaved Caspase (8 and 9), cleaved PARP, cIAP1, cIAP2, 
XIAP, LC3B, Beclin1, Cyclin A, Cyclin B1, Cyclin D1, and Cyclin 
E (Cell Signaling Technology, Danvers, MA, USA) and for 
Hsp90, ERBB2, and Bad (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) were used for immunoblotting.
Dose-response and synergy study
Bladder cancer cells were seeded on 96-well plates and were 
left to attach for 24 hours. For dose-response experiments, 
cells were treated with single and double combinations of 
NVP-BEZ235 (0.25–8.00 µM) or 17-DMAG (0.98–1000 nM) for 
24, 48, or 72 hours. Cytotoxic effects were evaluated by CCK-8 
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Fig. 1. Dose-response studies of cisplatin in human various bladder can-
cer cell lines. Human bladder cancer cells, including cisplatin-resistant 
T24R2, were exposed to increasing doses of cisplatin (0.039–40.0 µg/mL) 
for 48 hours, and changes in cell survival were assessed with the CCK-8 
assay. Each data point represents a mean of at least three biological 
replicates.
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Gaithersburg, MD, USA) according to the manufacturer’s pro-
tocol. Briefly, 10 µL of CCK-8 reagent was added to each well 
at the end of the incubation period, and the plates were fur-
ther incubated for 2 hours. Absorbance was read at an optical 
density of 450 nm, and cell viability was expressed as the sur-
viving fraction of cells in treated versus untreated controls.
The synergistic interaction between agents was quantita-
tively explored based on a combination index (CI) values us-
ing Calcusyn software (Biosoft, Ferguson, MO, USA) with the 
following interpretation: CI<1.0: synergism, CI>1.0: antago-
nism, and CI=1.0: additivity. The synergy between drugs was 
also assessed by a three-dimensional (3D) model using Mac-
Synergy II software, in which areas of the graph above zero in-
dicate synergism, while areas below zero indicate antagonism. 
The amount of synergy was expressed as surface area (µM/
mL2%), wherein 0–25, 25–50, 50–100, and >100 µM/mL2% in-
dicated insignificant, weak, moderate, and strong interactions, 
respectively. 
Clonogenic assay
For the colony-forming assay, T24R2 cells were seeded on a 
6-well plate at a concentration of 2×103 cells/mL and treated 
with NVP-BEZ235 (0.5 µM) and/or 17-DMAG (2.5 nM) for 48 
hours. Cells were cultured for another 2 weeks after removal 
of the drugs, and colonies formed were visualized by 0.4% 
crystal violet staining.
Flow cytometric cell cycle analysis
T24R2 cells were incubated with or without NVP-BEZ235 
(2 µM) or 17-DMAG (10 nM) for 48 hours, collected and fixed 
in 70% ethanol, and then, stained with a propidium iodide so-
lution [970 µL PBS, 40 µL of 1 mg/mL propidium iodide (Sig-
ma), and 3 µL of RNase A (Sigma)] for 30 minutes at 37°C. Af-
ter filtering with a strainer, the single-cell suspension was 
analyzed with a FACSCaliber flow cytometer (Becton-Dickin-
son, San Jose, CA, USA).
Western blot analysis 
Cells were lysed using RIPA buffer supplemented with com-
plete proteinase inhibitors (Roche, Basel, Switzerland). Cell 
lysates were then fractionated by SDS-PAGE and transferred 
to a PVDF membrane. Following blocking with 5% non-fat 
milk, the blots were incubated with corresponding primary 
antibodies and secondary antibodies. Signals were detected 
using a chemiluminescence Western blot substrate kit (Pierce, 
Rockford, IL, USA).
Statistical analysis
The data sets consisted of at least three biological replicates, 
and all statistical analyses were performed using SPSS 14.0 K 
software (SPSS Inc., Chicago, IL, USA). The data are expressed 
as a mean±SD. Statistical significance was determined by a 
two-sample t-test, and differences were considered significant 
at p<0.05.
RESULTS
Synergistic antitumor effect between 17-DMAG and 
NVP-BEZ235
Because HSP90 plays an import role as a chaperone in the ac-
tivation and stabilization of ERBB2 and its downstream sig-
nals (RAS-MEK-MAPK, PI3K-Akt-mTOR), we hypothesized 
that concomitant targeting of HSP90 and its downstream path 
could be a promising strategy with which to overcome cisplatin 
resistance in human BCa (Fig. 2). Dual PI3K/mTOR inhibitor 
NVP-BEZ235 exerted dose- and time-dependent antitumor ef-
fects in both T24 and T24R2 cells (Fig. 3A and B). However, the 
antitumor effect of NVP-BEZ235 was found to be self-limiting, 
with all measures of its antitumor impact reaching a plateau 
at a concentration around 0.5 µM. When T24 and T24R2 cells 
were exposed to escalating doses of the HSP90 inhibitor 17-
DMAG, the proliferation of both cell lines was suppressed in a 
dose- and time-dependent manner (Fig. 3C and D). Interest-
ingly, cisplatin-resistant T24R2 showed a relatively higher 
sensitivity to 17-DMAG treatment than the other human blad-
der cancer cell lines, including cisplatin-sensitive T24 (Fig. 4).
To investigate the synergistic interactions between two 
drugs, T24R2 cells were treated with escalating doses of 17-
DMAG alone or in a 1:200 fixed-ratio combination with NVP-
BEZ235, and the antitumor effects were evaluated by CCK-8 
assay (Fig. 5A). The correlation coefficients (r) were between 
0.792 and 0.982, indicating fair data conforming to the median 
effect principle (Table 1). The Dms (IC50s) of NVP-BEZ235 
and 17-DMAG were 2.08175 µM and 0.01942 µM, respective-
ly, while it was 0.00174 µM in combination treatment, sug-
gesting significant synergism between the two drugs. Fraction 
affected (fa) and CI analysis showed a CI<1 over a wide range 
RAS
Cell proliferation, cell survival, 


















Fig. 2. A schematic diagram of crosstalk between HSP90 and PI3K-AKT-
mTOR/RAS-MEK-MAPK pathways.
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of fractions affected (fa, 0.45–0.85). Clonogenic assay showed 
results compatible with the synergy test (Fig. 5E). For a more 
detailed analysis of synergism, four independent full combina-
tion studies with 17-DMAG and NVP-BEZ235 were performed 
to generate a 3D synergy plot using MacSynergy II software 
(Fig. 5D). The 3D analysis reflected strong synergy between 
the two drugs, with a synergy volume of 201.84 µM/mL2% and 
with minimal antagonism (-10.18 µM/mL2%). The colony-
forming assay results were compatible with the synergy test 
(Fig. 5E).
Combined treatment with 17-DMAG and NVP-BEZ235 
induces G1 and sub-G1 phase cell cycle arrest 
Treatment with neither 17-DMAG (10 nM) nor NVP-BEZ235 
(2.0 µM) alone elicited any significant alterations in cell cycle 
progression in T24R2 cells, whereas combined treatment re-
sulted in marked increases in cells in the sub-G1 (3.9±0.8%) 
and G1 (78.3±0.7%) phases, compared with untreated control 
(0.6±0.3% for sub-G1, 57.9±1.3% for G1 phase), 17-DMAG-
treated (1.4±0.2% for sub-G1, 59.4±1.0% for G1 phase), and 
NVP-BEZ235-treated (1.0±0.4% for sub-G1, 61.6±0.9% for G1 
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Fig. 3. Dose-response studies of 17-DMAG and NVP-BEZ235 in T24 and T24R2 cells. (A) Dose-response to NVP-BEZ235 in T24 cells. (B) Dose-response 
to NVP-BEZ235 in T24R2 cells. (C) Dose-response to 17-DMAG in T24 cells. (D) Dose-response to 17-DMAG in T24R2 cells. Both cell lines were exposed 
to escalating doses of 17-DMAG (0.098 nM–1 μM, upper panel) and NVP-BEZ235 (0.25–8.0 μM, lower panel) for 24, 48, and 72 hours, and cell survival 
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Fig. 4. Varying sensitivities of human bladder cancer cell lines to HSP90 
inhibitor 17-DMAG. Human bladder cancer cell lines [T24 (grade 3), 
T24R2, 253J (grade 4), HTB5 (grade 4), HTB9 (grade 2), UMUC14 (grade 
4), J82 (grade 3), and SW1710 (grade 3)] were treated with increasing 
doses of 17-DAMG (1.0 nM–1 μM) for 72 hours, and cell survival was 
evaluated with CCK-8 assay. *Significant difference between T24 and 
T24R2 (p<0.05). 
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Synergy mechanisms between 17-DMAG and 
NVP-BEZ235
Concomitant treatment of T24R2 cells with 17-DMAG and 
NVP-BEZ235 suppressed cyclin A and B expression while caus-
ing increased expression of cyclin D (Fig. 7). Also, the com-
bined treatment stimulated increased expression of caspase 
Concentration of NVP-BEZ235 (uM) and 17-DMAG (nM)













































































Fig. 5. Synergistic antitumor effects between 17-DMAG and NVP-BEZ235 in cisplatin-resistant T24R2 cells. (A) T24R2 cells were treated with escalating 
doses of 17-DMAG (2.5–20 nM) alone or in combination with NVP-BEZ235 (0.5–4.00 μM) at a 1:200 fixed ratio for 72 hours. Cell survival was assessed us-
ing CCK-8 assay. (B) Based on the results of the CCK-8 assay, fa-CI plots were generated in which fa and CI stand for fraction affected and CI values, re-
spectively. (C) For more accurate test of synergism between the two drugs, T24R2 cells were treated with a full combination of 17-DMAG (2.5–20 nM) and 
NVP-BEZ235 (0.5–4.00 μM) for 48 hours, and a 3D synergy plot was built using MacSynergy II data analysis. (D) Clonogenic assay of T24R2 cells treated with 
17-DMAG (2.5 nM) alone or in combination with NVP-BEZ235 (0.5 μM) for 48 hours. CI, combination index; fa, fraction affected; 3D, three-dimensional. 
C Concentration of NVP-BEZ235 (uM) and 17-DMAG (nM)
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8/9 and PARP cleavage while suppressing the expression of 
cIAP1 and cIAP2 (Fig. 7). There were no discernible changes in 
beclin 1, LC3B1, and LC3B2 expression in T24R2 cells after 
combined treatment with 17-DMAG and NVP-BEZ235 (Fig. 7). 
Although there was no significant change in HSP90 expression 
by drug treatment, combined treatment suppressed ERBB2 and 
its downstream signals (p-Akt, Akt, p-mTOR, mTOR, p-4E-BP1, 
p-GSK-3β) in T24R2 cells (Fig. 8).
DISCUSSION
Cisplatin-based chemotherapy is currently the gold standard 
for treating metastatic BCa. However, the survival benefit of 
the standard of care (SOC) has not seen improvement during 
the last few decades. A complete response is observed in only 
1 out of 4 patients. Such a high treatment failure rate may par-
tially be explained by the development of cisplatin resistance. 
Reduced cisplatin binding to DNA (pre-target resistance), re-
duced formation of DNA-cisplatin adducts (on-target resis-
tance), altered DNA damage response (post-target resistance), 
and influenced signaling pathways that reduce the DNA dam-
age response (off-target resistance) are believed to be viable 
mechanisms for cisplatin-resistance.14 Moreover, not all the 
patients are eligible for receiving a full therapeutic dose of cis-
platin, mostly due to decreased renal function. Such profiles 
prompt alternative plans for sensitizing bladder cancer cells 
to chemotherapy and reducing the dose of cisplatin while en-
forcing its therapeutic efficacy. Due to a better understanding 
of tumor biology, sequencing after the SOC or combinations of 
novel agents are being recognized as promising options in 
treating malignancies, including genitourinary cancers.      
There are several ongoing clinical trials of the treatment of 
advanced or metastatic urothelial carcinoma for both cisplat-
in-sensitive and -resistant cell lines. Various approaches, such 
as inhibitors of the mTOR, tyrosine kinase inhibitors, human 
epidermal growth factor receptor 2 (HER2) blockade, anti-an-
giogenic therapies, and immunotherapies, are being evaluat-
ed. Urothelial cancers are genetically complex with various on-
cogenic drivers and multiple mutations within a single tumor, 
gene fusion transcripts, copy number variations, and cytoge-
netic errors. Therefore, understanding the molecular mecha-
nisms underlying BCa is important to developing effective 
treatments for cisplatin-resistant BCa. Interestingly, Lee, et al.14 
revealed differential gene expression between T24 and T24R2 
cells using microarray analysis: when T24 cells became resis-
tant to cisplatin, various alterations were noted in the expres-
sion of genes controlling cell signaling, transcriptional regula-
tion, metabolism, cytoskeleton, immunity, growth factor, 
transporter, adhesion, and apoptosis.



















Fig. 6. Alterations in the cell cycle in T24R2 cells. T24R2 cells were treated with 17-DMAG (10 nM) alone or in combination with NVP-BEZ235 (2 μM) 
for 48 hours, and changes in cell cycle were evaluated by flow cytometry.
Table 1. Dose-Effect Relationships for 17-DMAG and NVP-BEZ235 in 
T24R2 Cells
Compound m* Dose (µM)† r
17-DMAG 1.185 0.01942 0.982
NVP-BEZ235 0.135 2.08175 0.792
Combination 0.425 0.00174 0.988
*Coefficient signifying dose-effect curve shape, †IC50 or dose causing 50% 
inhibition of cell proliferation.
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different types of cancer. HER2 belongs to the type 1 tyrosine 
kinase receptor family, which consists of four related receptors 
that form dimers with each other and is involved in cell cycle 
regulation and cell proliferation. Amplification of the HER2 
gene and overexpression thereof at the protein level have been 
shown to be associated with oncogenesis.1,15 In a healthy envi-
ronment, cells have low HER2 membrane protein content; 
however, but this is dramatically increased in cancer cells. 
Overexpression of HER2 protein has been reported in several 
malignancies, especially in gastric (20%) and breast cancers 
(up to 30%).16 In BCa, the expression frequency of HER2 has 
been reported to range from 25–100% in primary tumors and 
from 40–70% in corresponding metastases, which makes HER2 
an attractive target for systemic therapy.1 Studies have shown 
that HER2 overexpression is associated with disease aggressive-
ness and more unsatisfactory outcomes, suggesting HER2 tar-
geted therapy as a feasible option for locally advanced and met-
astatic HER2-amplified BCa.15,16 
When HER2 proteins dimerize and bind to a ligand, the 
PI3K-Akt-mTOR and RAF-MEK-ERK pathways are activated.17 
Signaling via the RAF-MEK-ERK cascade leads to phosphory-
lation of various proteins that have multiple cellular effects, 
mostly in cell cycle progression.18 Abnormal activation of the 
PI3K-Akt-mTOR signaling axis induces the development, pro-
gression, metastasis, and chemo-resistance in many tumors, 
including urothelial cancers.3 These findings have drawn at-
tention to PI3K and mTOR signaling as promising antitumor 
targets. PI3K activation is believed to be involved in cisplatin re-
sistance mechanisms through mutational activation of PI3K, 
PTEN loss, and activation of alternative receptor tyrosine ki-
nase. Such findings suggest the possible use of PI3K inhibitors 
in cisplatin-resistant cancers.6 Inhibition of mTOR has shown 
antitumor activity both in monotherapy and in combination 
with chemotherapy. In urothelial carcinoma cells, mTOR in-
hibition enhanced chemosensitivity by inducing cell cycle ar-
rest at the sub-G1 and G1 growth phases and inhibiting VEGF 
production. The first generation mTOR inhibitors (e.g., ra-
pamycin, temsirolimus, and everolimus) show synergistic ac-
tivity with cisplatin, but yield inadequate treatment responses.5 
These first generation mTOR inhibitors act by allosteric inhi-
bition of mTORC1, but not mTORC2, which induces paradox-
ical activation of a survival axis by mTORC2-mediated Akt 
phosphorylation.19,20 Therefore, the dual inhibition of PI3K/
mTOR or Akt/mTOR may overcome these feedback loops and, 
thus, prevent the development of resistance among cancer 
cells to targeted therapy. In support thereof, Moon, et al.3 dem-
onstrated a dose-dependent antitumor effect for the PI3K/
mTOR dual inhibitor NVP-BEZ235 in bladder cell lines. NVP-
BEZ235 blocked the negative feedback activation of Akt and 
showed a more significant antitumor effect, compared to the 
first generation rapalogues. However, NVP-BEZ235 mono-
therapy had an only partial inhibitory effect even at a relatively 
high dose (0.5 μM or higher) and showed a transient antitu-
mor effect lasting no more than 3 days. These findings were 
more pronounced in cisplatin-resistant T24R2 cells, compared 
to cisplatin-sensitive T24 cells, suggesting possible cross-resis-
tance between NVP-BEZ235 and cisplatin in human BCa. NVP-
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Fig. 7. Western blot analysis of proteins involved in apoptosis, cell cycle, and autophagy. T24R2 cells were treated with 17-DMAG (10 nM) alone or in 
combination with NVP-BEZ235 (2 μM) for 48 hours, and expressions of relevant proteins were evaluated by Western blot analysis.
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gistic antitumor effects by eliciting cell cycle arrest and caspase-
dependent apoptosis in cisplatin-resistant bladder cancer cells, 
compared to treatment with either agent alone. 
The activity of HER2 is affected and partly controlled by “mo-
lecular chaperones,” which assure accurate folding of pro-
teins, maintaining cellular integrity and homeostasis. In nor-
mal conditions, HSPs act as classical chaperones. Among 
several classes of HSPs, HSP90 is most abundant, and its loss 
of expression is related to poorer prognosis.7 Given that thera-
peutic resistance is attributed to diverse accumulating muta-
tions in cancer cells, targeting multiple anti-apoptotic path-
ways is ideal. There are HSP90 client proteins other than Akt 
and ERK that act as vital components of various oncogenic 
pathways related to growth and survival, such as hypoxia-in-
ducible factor-1a, erbB2, and inhibitor of κB kinase β, which 
mediates NF-κB activation.21 Since these molecules are deeply 
involved in significant cancer pathways and play essential roles 
as oncogenes, the ubiquitous molecular chaperone HSP90 is a 
promising candidate thought which to enhance treatment re-
sponses. In several malignancies, such as gastric and breast 
cancer, HSP90 expression has been shown to be significantly 
associated with tumor aggressiveness and poor prognosis. 
Anti-HSP90 treatment for these cancers has shown potent 
benefits in numerous preclinical and clinical studies.9,12,15,17,22,23 
In bladder cancer cells, 17-AAG clearly showed a dose-depen-
dent and cell type-specific inhibition of cell proliferation, sur-
vival, and motility.24 Yoshida, et al.25 suggested that HSP90 in-
hibitors, even at a low concentration (17-DMAG or 17-AAG at 
100 nM), would be potent enough to improve chemoradiation 
therapy responses by inactivating erbB2, Akt, and NF-κB with-
out increasing toxicities.6 Tatokoro, et al.21 demonstrated that 
administration of HSP90 inhibitors at noncytocidal concentra-
tions synergistically potentiated the cytotoxic effects of cisplat-
in on BCa-initiating cells in vitro and successfully sensitized 
cisplatin-resistant, BCa-initiating, cell-derived tumor xeno-
grafts to cisplatin.  These data suggest that it may be feasible to 
utilize HSP90 inhibitors to improve the therapeutic outcomes of 
cisplatin-based combination chemotherapy for advanced BCa.21 
Not only applying HSP90 inhibitor but combining it with 
other targeted therapies in conjunction with SOC may block 
compensatory signaling pathways and convey a clinical bene-
fit.5 An optimal strategy for the combination is to target the 
same pathway vertically.26 Since Akt is one of the client proteins 
of HSP90, we hypothesized that a combined regimen with an 
HSP90 inhibitor (17-DMAG) and a PI3K/mTOR dual inhibitor 
(NVP-BEZ235) could augment the relatively low antitumor ef-
fects of each agent in cisplatin-resistant bladder cancer cells. In 
line with previous results, the antitumor effect of NVP-BEZ235 
alone was self-limiting with an antitumor effect reaching a pla-
teau at a concentration around 0.5 μM. However, the prolifera-
tion of both T24 and T24R2 cells were suppressed in a dose- and 
time-dependent manner when exposed to escalating doses of 
HSP90 inhibitor 17-DMAG. Synergy tests for the combination 
of NVP-BEZ235 and 17-DMAG with cisplatin in cisplatin-resis-
tant bladder cancer cells also revealed significantly enhanced 
antitumor effects, compared to the effects of either drug alone. 
Fa-CI plots revealed that these two agents exert synergistic ef-
fects over a wide range of dose combinations in T24R2 cells. 
Dose reduction index analysis indicated that when this com-
bination is applied to treat T24R2 cells, the IC50 of NVP-BEZ235 
and 17-DMAG can be reduced by 1196.0- and 11.2- fold, re-
spectively, indicating strong synergistic interactions within two 
drugs. 3D synergy test demonstrated in a synergy volume of 
201.84 μM/mL2, with minimal antagonism, supporting the im-
portance of this effect in vivo. 
In human urinary bladder cancer cells, the diverse patterns 
of cell cycle arrest in response to 17-DMAG administration are 
associated with malignancy grade and cellular environment. 
Cell survival-related
-           +             -                   +         NVP-BEZ235































Fig. 8. Western blot analysis of proteins involved in cell survival. T24R2 
cells were treated with 17-DMAG (10 nM) alone or in combination with 
NVP-BEZ235 (2 μM) for 48 hours, and changes in cell survival-related 
protein expression were explored using Western blot analysis.
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Low malignancy p53wt cells, such as RT4, present with a prom-
inent G1/S block, while p53 mutant T24 cells exhibit various 
patterns of cell cycle arrest. In a previous study, a combination 
of NVP-BEZ235 and cisplatin showed prominent cytostatic ef-
fects, rather than apoptogenic effects, as was confirmed by a 
mild increase in sub-G1 fractions, and elicited a marked in-
crease in S phase fractions. In the present study, however, co-
treatment of 17-DMAG and NVP-BEZ235 provided a slight in-
crease in sub-G1 fractions and a marked increase in G1 phase 
cells in flow cytometry, suggesting prominent apoptotic ef-
fects. Western blot analysis demonstrated that the combined 
treatment resulted in a marked decrease in cyclin A and cyclin 
B, while causing increased expression of cyclin D. These find-
ings indicate that the antitumor mechanism of combined ther-
apy is at least partly through G2/M phase cell cycle arrest. More-
over, combined treatment with 17-DMAG and NVP-BEZ235 
suppressed the expression of anti-apoptotic proteins cIAP1 
and cIAP2 and enhanced the cleavage of caspase 8/9 and 
PARP, indicating induction of both extrinsic and intrinsic cas-
pase-dependent apoptotic pathways. Akt, which is a crucial 
protein kinase of the complex cell signaling network and an es-
sential member of the HSP90 complex, is downregulated upon 
17-DMAG administration. The exposure of T24R2 cells to 17-
DMAG in combination with NVP-BEZ235 suppressed the phos-
phorylation of PI3K, mTOR, and its immediate targets GSK-3β 
and 4E-BP1. Simultaneous suppression of PI3K and mTOR 
with the deactivation of Akt and its downstream signaling re-
flected the antiproliferative and proapoptotic activities of 17-
DMAG and NVP-BEZ235 in combination with cisplatin in cis-
platin-resistant bladder cancer cells. These results correspond 
with those reported by Chen, et al.,6 wherein combination of a 
PI3K/mTOR dual inhibitor (NVP-BEZ235) and HSP90 inhibi-
tor (NVP-AUY922) showed significant synergistic proapoptot-
ic and antiproliferative effects in cholangiocellular carcinoma 
cells in vitro. Furthermore, they demonstrated that the HSP 
inhibitor NVP-AUY922 induced ER stress and mitochondrial 
damage fueled by oxidative stress when combined with NVP-
BEZ235. There were no apparent changes in the expression of 
the autophagy-related genes beclin 1, LC3B1, and LC3B2 in 
T24R2 cells after combined treatment with 17-DMAG and NVP-
BEZ235.
Previous studies have shown that 17-DMAG simultaneously 
inactivates both Akt and ERK signaling at non-cytocidal con-
centrations when combined with cisplatin in human bladder 
cancer cells.21 In our study, however, the combination of NVP-
BEZ235 and 17-DMAG decreased the expression of PI3K-re-
lated proteins (Akt, mTOR) while increasing the expression of 
MERK-ERK-associated proteins. Activation of MAPK/ERK 
pathway signaling is known as a resistance mechanism in 
mTOR inhibitor-based therapy. Roccaro, et al.27 demonstrated 
that NVP-BEZ235 upregulates ERK phosphorylation in 
Waldenstrom macroglobulinemia cells. NVP-BEZ235 mono- 
and combination therapy with cisplatin in bladder cancer cell 
line upregulates MEK1/2, and ERK1/2.3 Thus, we suspect that 
17-DMAG did not reverse the effect of NVP-BEZ235 regarding 
ERK signaling. Such crosstalk indicates the MAPK/ERK path-
way as another potential concomitant target through which to 
enhance the antitumor effects of combination therapy in cis-
platin-resistant BCa.
The limitations of the current study include the in vitro study 
design and the small sample size. However, we were able to 
outline synergistic interactions between 17-DMAG and NVP-
BEZ235 in cisplatin-resistant BCa. Further comprehensive mo-
lecular studies, including in vivo studies, would be required to 
validate our findings and to further elucidate interactions be-
tween 17-DMAG and NVP-BEZ235 in cisplatin-resistant BCa.
In conclusion, combined treatment with the HSP90 inhibi-
tor 17-DMAG and the PI3K/mTOR survival pathway inhibitor 
NVP-BEZ235 showed synergistic antitumor effects of eliciting 
cell cycle arrest at the G1 phase and induction of caspase-de-
pendent apoptotic pathways in cisplatin-resistant bladder can-
cer cells.
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